Home / Stocks / HYPD

Hyperion Defi (HYPD, Pharmaceuticals) Stock Valuation & Fair Value No P/E valuation

Hyperion Defi (HYPD, Pharmaceuticals) trades at a blended P/E of 1.7, trading without a historical P/E to compare against, with a forward growth estimate of -17.5%. Analysts' one-year estimates have been hit 14% of the time.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-09-21
Blended P/E
1.7
Normal P/E
—
PEG
—
Fwd growth
-17.5%
Div yield
0.0%
RSI (14)
62.3
Neutral
Technical context
  • Price $3.92 at the 2026-09-23 close, 11.7% above the 20-day average ($3.51) and 28.1% above the 50-day ($3.06).
  • RSI (14) at 62.3.
  • 52-week range $2.34 to $11.83: the price is 66.9% below the high and 67.5% above the low.

The Street vs SeerForecast

Wall Street's mean price target for HYPD is $9.82 across 2 analysts, 150.6% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: we publish none, because it has no P/E to compare against its own history. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-09-14, because this company has no P/E to compare against its own history.

Blended P/E and rating by weekBlended P/E moved from 1.7 to 1.7 between 2026-09-14 and 2026-09-21, with 0 rating changes over 3 recorded weeks.2026-09-14: P/E 1.7, No P/E valuation2026-09-19: P/E 1.7, No P/E valuation (recalculated)2026-09-21: P/E 1.7, No P/E valuation1.71.71.7Sep 14Sep 16Sep 18Sep 19Sep 21
Attractively valuedNo P/E valuationAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-14P/E 1.7not availableNo P/E valuation
2026-09-19P/E 1.7not availableNo P/E valuation
2026-09-21P/E 1.7not availableNo P/E valuation ← now

Frequently asked questions

Is Hyperion Defi stock overvalued?

At a blended P/E of 1.7, Hyperion Defi has no historical normal P/E on record to compare that against. tickerseer therefore publishes no valuation rating for it.

What is Hyperion Defi's fair value and PEG?

Hyperion Defi trades at a blended P/E of 1.7, a forward growth estimate of -17.5%.

Has tickerseer's rating of Hyperion Defi changed?

tickerseer has published no valuation rating since 2026-09-14, because this company has no P/E to compare against its own history.

What is the analyst price target for Hyperion Defi?

The mean Wall Street price target for Hyperion Defi is $9.82 across 2 analysts, 150.6% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track HYPD free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.